Streetbeat News

Regulatory

RTX

Collins Aerospace, a subsidiary of RTX Corp (NYSE:RTX), is in discussions with NASA to withdraw from its contract to develop new spacesuits for the ISS. This marks a setback for NASA, which has faced issues with its aging spacesuits. Collins' withdrawal could leave future suit development to Axiom Space.

Portfolio Pulse from Vandana Singh

June 26, 2024 | 12:11 pm

VIR

Vir Biotechnology's combination drug for chronic hepatitis delta infection has received FDA clearance and Fast Track designation. The drug, consisting of tobevibart and elebsiran, is currently in Phase 2 trials with results expected in Q4.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:06 pm

EYPT

EyePoint Pharmaceuticals announced significant clinical and regulatory developments for its DURAVYU treatment, including Phase 3 trial designs for wet AMD and positive Phase 2 data. The company will webcast its R&D Day event today.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:06 pm

BCLI

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b clinical trial for NurOwn, an investigational therapy for amyotrophic lateral sclerosis (ALS).

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:05 pm

ANVS

Annovis Bio has filed a new patent for novel solid forms of Buntanetap with the U.S. Patent Office, building on a provisional patent from June 2023.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:01 pm

CBUS

Cibus Inc (NASDAQ:CBUS) has expanded its intellectual property coverage for ten gene editing and trait families, enhancing its patent portfolio in various geographies. This development strengthens Cibus' position in the gene editing market, particularly in agriculture.

Portfolio Pulse from Vandana Singh

June 26, 2024 | 12:00 pm

ANEW

ANEW Medical shares are trading higher after the company announced it has been granted a European patent for its Klotho gene sequence and gene delivery systems for treating neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:55 am

EVAX

Evaxion has announced that an international preliminary report on patentability for its AI-based novel cancer vaccine target identification method indicates promising prospects for obtaining granted patents and protecting the invention.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:32 am

LYEL

Lyell Immunopharma announced promising initial clinical and translational data from its Phase 1 trial of LYL797, a reprogrammed ROR1 CAR T-cell product for blood cancers. The trial showed dose-dependent antitumor activity in ROR1+ relapsed/refractory triple-negative breast cancer, with a 40% objective response rate and 60% clinical benefit rate at the highest dose. No significant safety issues were observed, and development is expanding into new tumor types. An IND submission for LYL119, a next-generation ROR1-targeted CAR T cell product, has been completed.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:10 am

NAK

Northern Dynasty Minerals Ltd. (NYSE:NAK) reports that two Alaska Native Village corporations, Iliamna Natives Limited and Alaska Peninsula Corporation, have filed a lawsuit against the EPA for vetoing the Pebble Project. The lawsuit claims the EPA exceeded its authority and ignored the potential economic benefits for local communities.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:08 am